Form 8-K - Current report:
SEC Accession No. 0001558370-23-019030
Filing Date
2023-11-14
Accepted
2023-11-14 16:19:09
Documents
15
Period of Report
2023-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fbio-20231114x8k.htm   iXBRL 8-K 39804
2 EX-99.1 fbio-20231114xex99d1.htm EX-99.1 253076
3 GRAPHIC fbio-20231114xex99d1001.jpg GRAPHIC 11899
  Complete submission text file 0001558370-23-019030.txt   484149

Data Files

Seq Description Document Type Size
4 EX-101.SCH fbio-20231114.xsd EX-101.SCH 4464
5 EX-101.DEF fbio-20231114_def.xml EX-101.DEF 14893
6 EX-101.LAB fbio-20231114_lab.xml EX-101.LAB 17168
7 EX-101.PRE fbio-20231114_pre.xml EX-101.PRE 14858
9 EXTRACTED XBRL INSTANCE DOCUMENT fbio-20231114x8k_htm.xml XML 7276
Mailing Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154
Business Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154 781-652-4500
Fortress Biotech, Inc. (Filer) CIK: 0001429260 (see all company filings)

IRS No.: 205157386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35366 | Film No.: 231406636
SIC: 2834 Pharmaceutical Preparations